Search


Current filters:
Start a new search
Add filters:

Use filters to refine the search results.


Results 31-40 of 181 (Search time: 0.003 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2005Dynamics of chronic myeloid leukaemiaMichor, F.; Hughes, T.; Iwasa, Y.; Branford, S.; Shah, N.; Sawyers, C.; Nowak, M.
2002Dual transcription of b2a2 and b3a2 BCR-ABL transcripts in chronic myeloid leukaemia is confined to patients with a linked polymorphism within the BCR geneBranford, S.; Hughes, T.; Rudzki, Z.
2000A novel BCR-ABL transcript (e8a2) with the insertion of an inverted sequence of ABL intron 1b in a patient with Philadelphia-positive chronic myeloid leukaemiaBranford, S.; Rudzi, Z.; Hughes, T.
2011Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cellsTang, M.; Gonen, M.; Quintas-Cardama, A.; Cortes, J.; Kantarjian, H.; Field, C.; Hughes, T.; Branford, S.; Michor, F.
2011Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up resultsKantarjian, H.; Giles, F.; Bhalla, K.; Pinilla-Ibarz, J.; Larson, R.; Gattermann, N.; Ottmann, O.; Hochhaus, A.; Radich, J.; Saglio, G.; Hughes, T.; Martinelli, G.; Kim, D.; Shou, Y.; Gallagher, N.; Blakesley, R.; Baccarani, M.; Cortes, J.; le Coutre, P.
2012Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinibWhite, D.; Radich, J.; Soverini, S.; Saunders, V.; Frede, A.; Dang, P.; Cilloni, D.; Lin, P.; Mongay, L.; Woodman, R.; Manley, P.; Slader, C.; Kim, D.; Pane, F.; Martinelli, G.; Saglio, G.; Hughes, T.
2011BCR-ABL transcript dynamics support the hypothesis that leukemic stem cells are reduced during imatinib teatmentStein, A.; Bottino, D.; Modur, V.; Branford, S.; Kaeda, J.; Goldman, J.; Hughes, T.; Radich, J.; Hochhaus, A.
2013Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemiaStein, A.; Martinelli, G.; Hughes, T.; Muller, M.; Beppu, L.; Gottardi, E.; Branford, S.; Soverini, S.; Woodman, R.; Hochhaus, A.; Kim, D.; Saglio, G.; Radich, J.
2014Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice dailyHughes, T.; Hochhaus, A.; Kantarjian, H.; Cervantes, F.; Guilhot, F.; Niederwieser, D.; Le Coutre, P.; Rosti, G.; Ossenkoppele, G.; Lobo, C.; Shibayama, H.; Fan, X.; Menssen, H.; Kemp, C.; Larson, R.; Saglio, G.
2015BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phaseHughes, T.; Saglio, G.; Quintás-Cardama, A.; Mauro, M.; Kim, D.; Lipton, J.; Bradley-Garelik, M.; Ukropec, J.; Hochhaus, A.